Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.62 |
| ▸ | HTR1A | P08908 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | MPO | P05164 | 7/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970036 | 0.90 | MPO (0.70) | HTR6HTR1AHTR2ADRD2HTR7 | |
| SCHEMBL17819281 | 0.86 | HTR2A (0.69) | HTR6HTR1AHTR2ADRD2HTR7 | |
| SCHEMBL30275112 | 0.86 | HTR2A (0.69) | HTR6HTR1AHTR2ADRD2HTR7 | |
| SCHEMBL2405163 | 0.84 | GPR84 (0.54) | HTR6HTR1AHTR2ASLC6A4GPR84 | |
| SCHEMBL1971950 | 0.84 | HTR2A (0.56) | HTR6HTR1AHTR2AHTR7BCHE | |
| SCHEMBL2402869 | 0.84 | GPR84 (0.51) | HTR6HTR1AMPOSLC6A4GPR84 | |
| SCHEMBL1970281 | 0.81 | MTNR1A (0.63) | HTR6HTR1AHTR2AMPONOTUM | |
| SCHEMBL1968351 | 0.81 | BCHE (0.67) | HTR1AHTR2ASLC6A4BCHEMTNR1A | |
| SCHEMBL26996489 | 0.80 | GPR84 (0.67) | HTR1AHTR2ADRD2MPOSLC6A4 | |
| SCHEMBL3348377 | 0.80 | HTR1A (0.49) | HTR6HTR1AMPOSLC6A4GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HTR6 177/4885HTR1A 56/4885HTR2A 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.